Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels. Goldman Sachs has just initiated coverage on ResMed and named it ...

Dave hadn't felt well before but had been told it was down to smoking, shift work, allergies, poor diet - and even his pillow ...

Read more. ResMed CPAP masks subject to Class I recall over magnetic interference issue Six reported injuries related to magnets on the headgear of CPAP machines by ResMed Ltd. have resulted in a ...

ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...

The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.